Screener
Regeneron Pharmaceuticals REGN Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| (In millions) / As of June 30, 2026 | Amortized / Cost Basis | Unrealized / Gains | Unrealized / Losses | Fair / Value |
|---|---|---|---|---|
| Certificates of deposit | 304.4 | — | (0.3) | 304.1 |
| Asset-backed securities | 193.2 | 0.2 | (0.3) | 193.1 |
| Sovereign bonds | 78.5 | 0.1 | (0.3) | 78.3 |
| $15,220.7 | $21.0 | $(52.5) | $15,189.2 | |
| As of December 31, 2025 | ||||
| Corporate bonds | $10,141.0 | $80.9 | $(2.4) | $10,219.5 |
| U.S. government and government agency obligations | 4,352.2 | 15.2 | (0.1) | 4,367.3 |
| Commercial paper | 540.8 | 0.3 | — | 541.1 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's unrealized gains on investments?
- Regeneron Pharmaceuticals (REGN) reported unrealized gains on investments of $21M in Q2 2026.
Ask your AI about Regeneron Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude